ALK’s new CEO offers no quick fixes, but says the drug group will take control of its destiny and its own products. He is certain that will allow the Danish company to release the potential that is tucked away in the organization.
Henrik Ørum, who co-founded Santaris, has launched a new biotech company with 40 million dollars in financial backing from a US investor. The startup has already signed a license deal with Roche, which bought Santaris in 2014, for a PCSK9 asset developed by his former company.
Oncology-focused biotech company Y-mAbs Therapeutics has raised USD 12 million in equity funding. The money will be used to support submission of a license application in the US for its lead candidate.
Novozymes spin out Albumedix has brought in an executive with experience from BioMarin and Novartis to serve as chief medical officer where he will help to advance the biotech’s development activities.
Danish biotech company Oncology Venture has secured million-dollar funding and the chance to add four new drug development projects to its pipeline. Meanwhile, it has launched a new US company that could eventually go public.
IO Biotech has secured millions from a trio of Danish venture investors as it prepares for a partnership or takeover in the coming years. 2017 could also prove the year when it brings in foreign investors.
Aarhus University is in the process of finding a new home for an invention that can be used in regenerative medicine and for testing new candidate drugs. They are already in talks with both domestic and foreign biotech companies.
In 2016, Lundbeckfond Emerge began using some of the DKK 300 million it has earmarked for new investments, adding two new companies to its portfolio. It is now launching a new initiative aimed at investing in projects in their infancy, says partner Christian Elling.
Genmab’s commercial partners have both hit a snag in the European regulatory system, with one of them withdrawing an application for a Genmab-developed drug and another having to answer additional questions about a second Genmab-developed medicine.
Roche's Chairman is a big fan of the Danish life science industry, the talent of which is among the chief reasons why the company is investing in Denmark. But he also cautions the country’s politicians.
Copenhagen and Malmö, the main constituents of the so-called Medicon Valley, will house Europe’s biggest biotech conference, BIO-Europe, in 2018. It could pave the way for increased export and investment in the region, says Novo Nordisk.
Genmab’s bone marrow cancer treatment has delivered the goods with fresh data presented at a hematology conference in San Diego. It reinforces the drug’s position in the market and the entire future foundation for the Danish biotech company, says an analyst.
Although Novo Nordisk has discontinued its activities in what CSO Mads Krogsgaard Thomsen has previously called the Holy Grail of diabetes care, he is not resigned to letting go completely. A partnership with the world’s most cited researcher could bring Novo back in the game. But for now, he has turned his attention to another Holy Grail.